Table 19 Recombinant Human Erythropoietin for Healing of Pressure Injuries

Author Year

Country
Research Design
Sample Size

Methods Outcome

Vair et al. 2015

Canada

Pre-post

N=4

 

Population: Mean age=57 yr; Gender: males=2, females=2; Pressure injury stage: III=3, IV=1.

Intervention: Participants with non-healing ulcers and low hemoglobin levels received recombinant human erythropoietin (rhuEPO) injections of 75 IU/kg, 3 times/wk, for 6 wk in addition to regular care.

Outcomes: Wound surface area; Wound depth.

1.     Wound healing results were variable among participants, with no significant differences from baseline to 8 and 20 wk follow-up in terms of wound surface area and wound depth.

Keast & Fraser 2004

Canada

Pre Post

N=4

Population: Mean age: 59 yr; Gender: males=4, females=0.

Intervention: Six wk of recombinant human erythropoietin (75 IU/kg, three times per wk), in addition to regular rehabilitation practice (inpatient and outpatient).

Outcome Measures: Hemoglobin count; Pressure injury quantity, area and depth.

1.     Day 1: Mean hemoglobin=88g/L; Mean ulcer surface area=42.3cm2; Mean ulcer depth=2.3cm.

2.     End of wk 6: Mean hemoglobin=110g/L. Mean ulcer surface=38.4cm2; Mean ulcer depth=1.2cm.

top